Radiotherapy following radical prostatectomy

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Mohler J, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl Compr. Canc. Netw.8(2), 162–200 (2010).
   PubMedGoogle Scholar
• Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol.28(7), 1117–1123 (2010).
   PubMed Web of Science ®Google Scholar
• Schaeffer EM, Loeb S, Walsh PC. The case for open radical prostatectomy. Urol. Clin. North Am.37(1), 49–55 (2010).
   Google Scholar
• Stephenson AJ, Kattan MW, Eastham JA et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J. Clin. Oncol.24(24), 3973–3978 (2006).
   PubMed Web of Science ®Google Scholar
• Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J. Urol.150(1), 135–141 (1993).
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol.23(28), 7005–7012 (2005).
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Wood DP, Kattan MW et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J. Urol.182(4), 1357–1363 (2009).
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet366(9485), 572–578 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA296(19), 2329–2335 (2006).
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol.181(3), 956–962 (2009).
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J. Clin. Oncol.27(18), 2924–2930 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cangh PJ, Richard F, Lorge F et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J. Urol.159(1), 164–166 (1998).
   PubMed Web of Science ®Google Scholar
• Moinpour CM, Hayden KA, Unger JM et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J. Clin. Oncol.26(1), 112–120 (2008).
   PubMed Web of Science ®Google Scholar
• Ghia AJ, Shrieve DC, Tward JD. Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology76(5), 1169–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffman KE, Nguyen PL, Chen M-H et al. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J. Urol.185(1), 116–120 (2011).
   PubMedGoogle Scholar
• Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA291(11), 1325–1332 (2004).
   PubMed Web of Science ®Google Scholar
• Elliott SP, Wilt TJ, Kuntz KM. Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis. Prost. Cancer Prost. Dis.14(3), 270–277 (2011).
   Google Scholar
• Trock BJ, Han M, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA299(23), 2760–2769 (2008).
   PubMed Web of Science ®Google Scholar
• Cotter SE, Chen MH, Moul JW et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer117(17), 3925–3932 (2011).
   Google Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA281(17), 1591–1597 (1999).
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Klein EA. Is there a standard of care for pathologic stage T3 prostate cancer? J. Clin. Oncol.27(18), 2898–2899 (2009).
   Google Scholar
• D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA299(3), 289–295 (2008).
   PubMed Web of Science ®Google Scholar
• Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol.11(11), 1066–1073 (2010).
   PubMed Web of Science ®Google Scholar
• Denham JW, Steigler A, Lamb DS et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol.12(5), 451–459 (2011).
   PubMed Web of Science ®Google Scholar
• Cheung R, Kamat AM, de Crevoisier R et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int. J. Radiat. Oncol. Biol. Phys.63(1), 134–140 (2005).
   PubMedGoogle Scholar
• King C, Presti J, Gill H, Brooks J, Hancock S. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int. J. Radiat. Oncol. Biol. Phys.59(2), 341–347 (2004).
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of Phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys.61(5), 1285–1290 (2005).
   PubMed Web of Science ®Google Scholar
• Corn BW, Winter K, Pilepich MV. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. Urology54(3), 495–502 (1999).
   PubMed Web of Science ®Google Scholar
• Shipley W, Hunt D, Lukka H et al. Initial Report of RTOG 9601: a Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2–3, N0 Disease, and Elevated PSA Levels. Int. J. Radiat. Oncol. Biol. Phys.78(3S), S27 (2010).
   Google Scholar
• Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology47(2), 225–231 (1996).
   PubMed Web of Science ®Google Scholar
• Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology219(2), 432–439 (2001).
   PubMed Web of Science ®Google Scholar
• Sella T, Schwartz LH, Swindle PW et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology231(2), 379–385 (2004).
   PubMed Web of Science ®Google Scholar
• Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. Am. J. Roentgenol.168(2), 379–385 (1997).
   PubMed Web of Science ®Google Scholar
• Michalski JM, Lawton C, El Naqa I et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.76(2), 361–368 (2010).
   PubMed Web of Science ®Google Scholar
• Koontz BF, Das S, Temple K et al. Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy. Med. Dosim.34(3), 256–260 (2009).
   Google Scholar
• Kupelian P, Langen K, Willoughby T, Wagner T, Zeidan O, Meeks S. Daily variations in the position of the prostate bed in patients with prostate cancer receiving postoperative external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.66(2), 593–596 (2006).
   Google Scholar
• Ost P, De Meerleer G, De Gersem W, Impens A, De Neve W. Analysis of prostate bed motion using daily cone-beam computed tomography during postprostatectomy radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.79(1), 188–194 (2011).
   PubMed Web of Science ®Google Scholar
• Ost P, Lumen N, Goessaert AS et al. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur. Urol. (2011).
   Google Scholar
• Ost P, De Troyer B, Fonteyne V, Oosterlinck W, De Meerleer G. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.80(5), 1316–1322 (2011).
   PubMed Web of Science ®Google Scholar
• Kruser TJ, Jarrard DF, Graf AK et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer117(12), 2629–2636 (2011).
   PubMed Web of Science ®Google Scholar
• Asbell SO, Krall JM, Pilepich MV et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int. J. Radiat. Oncol. Biol. Phys.15(6), 1307–1316 (1988).
   PubMed Web of Science ®Google Scholar
• Pommier P, Chabaud S, Lagrange JL et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J. Clin. Oncol.25(34), 5366–5373 (2007).
   PubMed Web of Science ®Google Scholar
• Roach M 3rd, DeSilvio M, Lawton C et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J. Clin. Oncol.21(10), 1904–1911 (2003).
   PubMed Web of Science ®Google Scholar
• Spiotto M, Hancock S, King C. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int. J. Radiat. Oncol. Biol. Phys.69(1), 54–61 (2007).
   PubMed Web of Science ®Google Scholar